StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) shareholders

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302545% above fair value
$411.29−5.25 (-1.26%)

Close on Nov 16, 2026Market cap $46.76BP/E 73.6Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
35M
Shares held, 13F filers
Institutional holders
283
46 new, 63 sold out
Net institutional buying
-2M
In Q2 2026
Insider trades, 12 months
0 buys · 207 sales
Net sold $386.23M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Felix J. Baker
Joint filing with Julian C. Baker (8.00%), Baker Bros. Advisors LP (8.00%) and 1 more
115,918,3138.00%13D (active) amendmentApr 16, 2026
Julian C. Baker
Joint filing with Felix J. Baker (7.80%), Baker Bros. Advisors LP (7.80%) and 1 more
115,912,8147.80%13D (active) amendmentSep 14, 2026
HHLR Advisors, Ltd.
Joint filing with Hillhouse Investment Management, Ltd. (6.70%)
92,805,7416.70%13D (active) amendmentMar 3, 2025
John V. Oyler71,464,8085.20%13G (passive) amendmentDec 31, 2023

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ONCValueChange% of portfolio
Baker Bros. Advisors LP8,801,567–$2.51B+2,51412.57%
Primecap Management Co/Ca/5,007,931–$1.43B+32,7500.84%
Capital International Investors4,210,221–$1.20B+51,4950.25%
FMR LLC2,478,527–$706.31M−1,215,0830.03%
Capital World Investors2,249,582–$641.06M+626,8950.08%
Citadel Advisors LLC1,425,517–$406.23M+375,2810.05%
Temasek Holdings (Private) Ltd845,729–$241.01M−16,9140.65%
Price T Rowe Associates Inc /Md/758,752–$216.22M+218,9830.02%
BlackRock, Inc.694,618–$197.95M+34,1170.00%
Millennium Management LLC543,323–$154.83M+338,4770.06%
Morgan Stanley497,437–$141.75M+4,9780.01%
Siren, L.L.C.465,000–$132.51M–2.68%
Bank Of America Corp /De/439,336–$125.20M+34,0630.01%
Baird Financial Group, Inc.368,978–$105.15M+19,3270.14%
Man Group plc307,463–$87.62M+65,5410.14%
Capital International, Inc./CA/305,477–$87.05M+3,2340.61%
Candriam S.C.A.289,735–$82.49M+30,0040.37%
Two Sigma Investments, LP286,552–$81.66M+253,0090.06%
UBS Group AG258,589–$73.69M−207,3000.01%
Arrowstreet Capital, Limited Partnership249,758–$71.17M+139,1720.03%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares heldNew / addedReduced / closedShares boughtShares sold
Q2 202628335M46 / 11084 / 633M6M
Q1 202630738M42 / 11788 / 496M4M
Q4 202531837M67 / 11775 / 362M2M
Q3 202529236M60 / 10280 / 423M3M
Q2 202527436M31 / 9689 / 531M9M
Q1 202529744M71 / 9979 / 266M7M
Q4 202425645M40 / 8880 / 333M6M
Q3 202425248M57 / 5396 / 264M3M
Q2 202422348M23 / 7771 / 231M2M
Q1 202422549M42 / 9746 / 434M5M
Q4 202322951M48 / 5876 / 292M5M
Q3 202321554M21 / 7567 / 307M2M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

120 funds held ONC in Q2 2026, 8% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ONCValue% of fundAs of
New Perspective Fund2,663,960–$759.15M0.45%Jun 30, 2026
Vanguard Primecap Fund2,347,622–$669.00M0.70%Jun 30, 2026
Vanguard Capital Opportunity Fund1,182,071–$336.85M1.03%Jun 30, 2026
EUPAC Fund700,821–$199.71M0.14%Jun 30, 2026
New World Fund Inc677,287–$214.03M0.24%Jul 31, 2026
PRIMECAP Odyssey Aggressive Growth Fund646,087–$204.17M2.76%Jul 31, 2026
Fidelity Growth Company Fund624,896–$179.92M0.18%May 31, 2026
PRIMECAP Odyssey Growth Fund585,087–$184.89M3.05%Jul 31, 2026
iShares Biotechnology ETF564,180–$160.77M1.77%Jun 30, 2026
New Economy Fund399,178–$114.93M0.22%May 31, 2026
American Funds Global Insight Fund374,007–$118.19M0.55%Jul 31, 2026
T. Rowe Price International Stock Fund261,437–$82.62M0.62%Jul 31, 2026
First Trust NYSE Arca Biotechnology Index Fund245,095–$69.84M2.48%Jun 30, 2026
Baird Chautauqua International Growth Fund179,205–$51.07M3.91%Jun 30, 2026
Fidelity Growth Company K6 Fund174,859–$50.35M0.18%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
John OylerChief Executive Officer, Director7,815,448Aug 12, 2026
Titus B. BallPrincipal Accounting Officer0Nov 10, 2026
Chan Henry LeeSVP, General Counsel0Nov 9, 2026
Xiaobin WuPresident and COO4,000Aug 27, 2026
Aaron RosenbergChief Financial Officer0Aug 5, 2026
Lai WangPresident, Global Head of R&D601,965Jun 25, 2026
Xiaodong WangDirector4,586,980Nov 12, 2026
Bros. Advisors Lp BakerDirector922,957Sep 16, 2026
Brothers Life Sciences LP BakerDirector8,229,958Sep 16, 2026
Felix BakerDirector997,946Sep 16, 2026
Bros. Advisors (GP) LLC BakerDirector730,643Sep 16, 2026
667, L.P.Director10,803,789Sep 16, 2026
Julian BakerDirector10,734,144Sep 16, 2026
Elizabeth Fisher MooneyDirector18,980Jun 15, 2026
Margaret DuganDirector73,164Jun 15, 2026
Anthony C. HooperDirector83,720Jun 15, 2026
Shalini SharpDirector38,116Jun 15, 2026
Olivier BrandicourtDirector46,306Jun 15, 2026
Alessandro RivaDirector73,164Jun 15, 2026
Charles Lazelle SawyersDirector1,946Jun 15, 2026
Qingqing YiDirector0Jun 3, 2026
Corazon (Corsee) D. SandersDirector0May 27, 2026
Hillhouse Investment Management, Ltd.10% owner125,045,741Dec 4, 2024
Hhlr Advisors, Ltd.10% owner142,888,241Dec 4, 2024

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Xiaodong Wang
Director
Nov 9, 2026Gift−1,183––4,586,930
Titus B. Ball
Principal Accounting Officer
Nov 6, 2026Sale−26$406.34$10.56K0
Titus B. Ball
Principal Accounting Officer
Nov 6, 2026Sale−1,533$405.55$621.71K26
Titus B. Ball
Principal Accounting Officer
Nov 6, 2026Option exercise+679$159.03$107.98K1,559
Titus B. Ball
Principal Accounting Officer
Nov 6, 2026Option exercise+880$207.55$182.64K880
Chan Henry Lee
SVP, General Counsel
Nov 5, 2026Sale(10b5-1 plan)−455$402.00$182.91K0
Chan Henry Lee
SVP, General Counsel
Nov 5, 2026Sale(10b5-1 plan)−660$400.00$264.00K455
Xiaodong Wang
Director
Oct 27, 2026Sale(10b5-1 plan)−6,903$366.22$2.53M0
Xiaodong Wang
Director
Oct 27, 2026Sale(10b5-1 plan)−3,965$365.43$1.45M6,903
Xiaodong Wang
Director
Oct 27, 2026Sale(10b5-1 plan)−2,841$363.95$1.03M10,868
Xiaodong Wang
Director
Oct 27, 2026Sale(10b5-1 plan)−8,148$363.24$2.96M13,709
Xiaodong Wang
Director
Oct 27, 2026Sale(10b5-1 plan)−2,331$362.35$844.64K21,857
Xiaodong Wang
Director
Oct 27, 2026Sale(10b5-1 plan)−320$360.64$115.40K24,188
Xiaodong Wang
Director
Oct 27, 2026Sale(10b5-1 plan)−1,280$359.72$460.44K24,508
Xiaodong Wang
Director
Oct 27, 2026Sale(10b5-1 plan)−1,681$358.75$603.05K25,788
Xiaodong Wang
Director
Oct 27, 2026Sale(10b5-1 plan)−1,239$357.54$442.99K27,469
Xiaodong Wang
Director
Oct 27, 2026Sale(10b5-1 plan)−1,440$355.62$512.09K28,708
Xiaodong Wang
Director
Oct 27, 2026Sale(10b5-1 plan)−880$355.56$312.89K30,148
Xiaodong Wang
Director
Oct 27, 2026Option exercise+31,028$36.90$1.14M31,028
Xiaodong Wang
Director
Oct 13, 2026Sale(10b5-1 plan)−1,260$353.24$445.08K0
Xiaodong Wang
Director
Oct 13, 2026Sale(10b5-1 plan)−6,558$352.57$2.31M1,260
Xiaodong Wang
Director
Oct 13, 2026Sale(10b5-1 plan)−5,681$351.40$2.00M7,818
Xiaodong Wang
Director
Oct 13, 2026Sale(10b5-1 plan)−10,361$350.47$3.63M13,499
Xiaodong Wang
Director
Oct 13, 2026Sale(10b5-1 plan)−7,167$349.56$2.51M23,860
Xiaodong Wang
Director
Oct 13, 2026Option exercise+31,027$36.90$1.14M31,027
Chan Henry Lee
SVP, General Counsel
Sep 30, 2026Sale(10b5-1 plan)−1,115$375.00$418.13K0
Xiaodong Wang
Director
Sep 28, 2026Sale(10b5-1 plan)−4,239$362.17$1.54M24,228
Xiaodong Wang
Director
Sep 28, 2026Sale(10b5-1 plan)−14,525$366.58$5.32M738
Xiaodong Wang
Director
Sep 28, 2026Sale(10b5-1 plan)−2,047$365.85$748.89K15,263
Xiaodong Wang
Director
Sep 28, 2026Sale(10b5-1 plan)−3,419$364.07$1.24M17,310
Xiaodong Wang
Director
Sep 28, 2026Sale(10b5-1 plan)−3,499$363.10$1.27M20,729
Xiaodong Wang
Director
Sep 28, 2026Sale(10b5-1 plan)−738$367.23$271.02K0
Xiaodong Wang
Director
Sep 28, 2026Sale(10b5-1 plan)−2,241$361.05$809.11K28,467
Xiaodong Wang
Director
Sep 28, 2026Sale(10b5-1 plan)−40$359.16$14.37K30,708
Xiaodong Wang
Director
Sep 28, 2026Sale(10b5-1 plan)−120$358.71$43.05K30,748
Xiaodong Wang
Director
Sep 28, 2026Sale(10b5-1 plan)−160$356.97$57.12K30,868
Xiaodong Wang
Director
Sep 28, 2026Option exercise+31,028$36.90$1.14M31,028
Bros. Advisors Lp Baker
Director
Sep 14, 2026Option exercise+30,768$36.83$1.13M761,410
Bros. Advisors Lp Baker
Director
Sep 14, 2026Option exercise+30,768$36.83$1.13M8,099,179
Xiaodong Wang
Director
Sep 8, 2026Sale(10b5-1 plan)−6,278$351.25$2.21M0
Xiaodong Wang
Director
Sep 8, 2026Sale(10b5-1 plan)−2,841$346.16$983.44K3,238
Xiaodong Wang
Director
Sep 8, 2026Sale(10b5-1 plan)−1,517$347.39$526.99K1,721
Xiaodong Wang
Director
Sep 8, 2026Sale(10b5-1 plan)−1,721$348.01$598.93K0
Xiaodong Wang
Director
Sep 8, 2026Sale(10b5-1 plan)−6,569$350.27$2.30M6,278
Xiaodong Wang
Director
Sep 8, 2026Sale(10b5-1 plan)−1,181$345.38$407.89K6,079
Xiaodong Wang
Director
Sep 8, 2026Option exercise+31,027$36.90$1.14M31,027
Xiaodong Wang
Director
Sep 8, 2026Sale(10b5-1 plan)−7,492$348.31$2.61M23,535
Xiaodong Wang
Director
Sep 8, 2026Sale(10b5-1 plan)−10,688$349.28$3.73M12,847
Titus B. Ball
Principal Accounting Officer
Sep 1, 2026Sale−132$355.86$46.97K0
Xiaobin Wu
President and COO
Aug 25, 2026Sale(10b5-1 plan)−280$380.00$106.40K0
John Oyler
Chief Executive Officer, Director
Aug 12, 2026Sale(10b5-1 plan)−20,899$358.41$7.49M14,102
John Oyler
Chief Executive Officer, Director
Aug 12, 2026Sale(10b5-1 plan)−15,396$357.63$5.51M35,001
John Oyler
Chief Executive Officer, Director
Aug 12, 2026Sale(10b5-1 plan)−2,515$356.43$896.42K50,397
John Oyler
Chief Executive Officer, Director
Aug 12, 2026Sale(10b5-1 plan)−1,980$354.71$702.33K52,912
John Oyler
Chief Executive Officer, Director
Aug 12, 2026Sale(10b5-1 plan)−14,102$359.12$5.06M0
Chan Henry Lee
SVP, General Counsel
Aug 11, 2026Option exercise+812$194.47$157.91K812
Chan Henry Lee
SVP, General Counsel
Aug 11, 2026Option exercise+1,058$213.32$225.69K1,870
Chan Henry Lee
SVP, General Counsel
Aug 11, 2026Option exercise+796$159.03$126.59K2,666
Chan Henry Lee
SVP, General Counsel
Aug 11, 2026Sale(10b5-1 plan)−2,666$360.00$959.76K0
John Oyler
Chief Executive Officer, Director
Aug 11, 2026Sale(10b5-1 plan)−4$367.00$1.47K54,892

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
2M shares short
Days to cover
4.4
At 0M shares a day
Change since last report
-10.6%
From 2M shares
Short volume, 20 days
58.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BeOne Medicines's stock actually held short. Settlement fails (shares not delivered on time) peaked at 27,633 shares on Sep 29, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Titus B. Ball
Officer
Nov 6, 20261,559$632.28KNov 6, 2026Exercise of Options Under a Registered Plan
Chan Henry Lee
Officer
Nov 5, 20261,115$421.22KNov 5, 2026Restricted Stock Units
Chan Henry Lee
Officer
Sep 30, 20261,115$407.28KSep 30, 2026Restricted Stock Units
Xiaodong Wang
Director, Chair, Scientific Advisory Brd
Sep 8, 2026131,370$47.06MSep 8, 2026Exercise of Stock Options
Titus B. Ball
Officer
Sep 1, 2026132$46.97KSep 1, 2026Restricted Stock Vesting Under a Registered Plan
Corazon (Corsee) D. Sanders
Former Director
Aug 25, 20262,075$788.50KAug 25, 2026Exercise of Options Under a Registered Plan
Xiaobin Wu
Officer
Aug 25, 202615,000$5.58MAug 25, 2026Restricted Stock Units
Chan Henry Lee
Officer
Aug 11, 20262,002$718.72KAug 11, 2026Exercise of Stock Options
John Oyler
Director, Officer
Aug 10, 2026240,810$83.87MAug 10, 2026Previously Exercised Stock Options
Aaron Rosenberg
Officer
Aug 3, 20261,157$361.81KAug 3, 2026Restricted Stock Vesting Under a Registered Plan
Chan Henry Lee
Officer
Jul 30, 20261,044$337.93KJul 30, 2026Restricted Stock Vesting Under a Registered Plan
Chan Henry Lee
Officer
Jul 22, 20262,001$637.69KJul 22, 2026Exercise of Stock Options
John Oyler
Director, Officer
Jul 14, 2026513,574$156.11MJul 14, 2026Exercise of Stock Options
Pan-Oyler Foundation
Director, Officer
Jul 10, 202649,541$15.00MJul 10, 2026Founders Shares
John Oyler
Director, Officer
Jul 10, 2026150,000$45.42MJul 10, 2026Exercise of Stock Options

See a number that looks wrong?